Dupilumab in Moderate-to-Severe Atopic Dermatitis With or Without Comorbid Asthma: Pooled Analysis of 2 Randomized Phase 3 Trials (LIBERTY AD SOLO 1 & 2)

Endpoints included proportion of patients with Investigator’s Global Assessment (IGA) 0/1, >=75% improvement in Eczema Area and Severity Index (EASI-75), and peak pruritus Numerical Rating Scale (NRS) improvement >=4. Conclusions This subgroup analysis shows that dupilumab-treated patients wit...

Full description

Saved in:
Bibliographic Details
Published inJournal of allergy and clinical immunology Vol. 141; no. 2; p. AB132
Main Authors Deleuran, Mette, Guttman-Yassky, Emma, Kingo, Kulli, Graham, Neil M.H., Pirozzi, Gianluca, Akinlade, Bolanle, Eckert, Laurent, Gadkari, Abhijit, Ardeleanu, Marius
Format Journal Article
LanguageEnglish
Published St. Louis Elsevier Inc 01.02.2018
Elsevier Limited
Subjects
Asthma
Atopic dermatitis
Comorbidity
Dermatitis
Eczema
Immunotherapy
Monoclonal antibodies
Pruritus
Online AccessGet full text

Cover

More Information
Summary:Endpoints included proportion of patients with Investigator’s Global Assessment (IGA) 0/1, >=75% improvement in Eczema Area and Severity Index (EASI-75), and peak pruritus Numerical Rating Scale (NRS) improvement >=4. Conclusions This subgroup analysis shows that dupilumab-treated patients with and without comorbid asthma have comparable/significant improvement in AD signs and symptoms.
ISSN:0091-6749
1097-6825
DOI:10.1016/j.jaci.2017.12.420